Peter Chatfield

716 total citations
7 papers, 59 citations indexed

About

Peter Chatfield is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Peter Chatfield has authored 7 papers receiving a total of 59 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Peter Chatfield's work include Prostate Cancer Treatment and Research (6 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and PARP inhibition in cancer therapy (3 papers). Peter Chatfield is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and PARP inhibition in cancer therapy (3 papers). Peter Chatfield collaborates with scholars based in United Kingdom, New Zealand and Brazil. Peter Chatfield's co-authors include Emma Hall, Mohini Varughese, Aude Espinasse, Johann S. de Bono, Isabel Syndikus, Susana Miranda, Christy Ralph, Omi Parikh, Tony Elliott and Simon J. Crabb and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Therapeutic Advances in Medical Oncology.

In The Last Decade

Peter Chatfield

7 papers receiving 59 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Chatfield United Kingdom	4	41	40	22	14	9	7	59
Swapnil Parmar United States	5	43 1.0×	30 0.8×	20 0.9×	6 0.4×	7 0.8×	10	72
E Paris France	2	38 0.9×	44 1.1×	27 1.2×	6 0.4×	4 0.4×	2	77
Brian Hanratty United States	6	22 0.5×	52 1.3×	40 1.8×	8 0.6×	7 0.8×	10	89
Adam Donoghue Canada	2	26 0.6×	69 1.7×	29 1.3×	15 1.1×	5 0.6×	2	86
Annette Kolodzie United States	4	35 0.9×	20 0.5×	17 0.8×	5 0.4×	7 0.8×	6	58
Beshara Sheehan United Kingdom	2	19 0.5×	51 1.3×	19 0.9×	27 1.9×	3 0.3×	5	64
Archana Ajmera United States	3	36 0.9×	38 0.9×	18 0.8×	9 0.6×	2 0.2×	13	49
Linnea Fulton United States	5	55 1.3×	64 1.6×	20 0.9×	9 0.6×	2 0.2×	6	80
Chengzhi Zhou China	5	40 1.0×	47 1.2×	17 0.8×	6 0.4×	3 0.3×	17	62
R. Coleman United States	4	27 0.7×	20 0.5×	5 0.2×	20 1.4×	8 0.9×	18	49

Countries citing papers authored by Peter Chatfield

Since Specialization

Citations

This map shows the geographic impact of Peter Chatfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Chatfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Chatfield more than expected).

Fields of papers citing papers by Peter Chatfield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Chatfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Chatfield. The network helps show where Peter Chatfield may publish in the future.

Co-authorship network of co-authors of Peter Chatfield

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Chatfield. A scholar is included among the top collaborators of Peter Chatfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Chatfield. Peter Chatfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Parker, Chris, Nina Tunariu, Holly Tovey, et al.. (2023). Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response. JNCI Cancer Spectrum. 7(6). 3 indexed citations

Tunariu, Nina, Holly Tovey, Roberto Alonzi, et al.. (2021). Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223. Clinical Genitourinary Cancer. 19(5). e299–e305. 9 indexed citations

Banerjee, Susana, Holly Tovey, Rebecca Bowen, et al.. (2020). Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037). Therapeutic Advances in Medical Oncology. 12. 3863590392–3863590392. 5 indexed citations

Alonzi, Roberto, Chris Parker, Nina Tunariu, et al.. (2019). Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 37(15_suppl). e16513–e16513. 2 indexed citations

Mateo, Joaquı́n, Núria Porta, Ursula McGovern, et al.. (2019). TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.. Journal of Clinical Oncology. 37(15_suppl). 5005–5005. 36 indexed citations

Parker, Chris, Roberto Alonzi, Nina Tunariu, et al.. (2018). Radium-223: Disease response and fracture assessment by whole body diffusion-weighted MRI (WB-DWMRI) in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 36(15_suppl). 5024–5024. 2 indexed citations

Banerjee, Susana, Lucy Kilburn, Rebecca Bowen, et al.. (2016). Principal results of the cancer of the ovary abiraterone trial (CORAL): A phase II study of abiraterone in patients with recurrent epithelial ovarian cancer (CRUKE/12/052). Annals of Oncology. 27. vi569–vi569. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact